Temasek Holdings
http://www.temasekholdings.com.sg/Temasek Holdings is an Asian investment firm headquartered in Singapore. Its portfolio spans various industries including telecommunications & media, financial services, real estate, transportation & logistics, energy & resources, infrastructure, engineering & technology as well as bioscience & healthcare. As of March 2007, the net value of its portfolio is more than US$100 billion, concentrated principally in Singapore, Asia and the OECD economies. Temasek's total shareholder return since its inception in 1974 has been more than 18% compounded annually. It has a corporate credit rating of AAA/Aaa by rating agencies Standard & Poor's and Moody's respectively.
In December of 2007, Temasek Holdings invested $4.4 billion in Merrill Lynch (NYSE: MER) common stock.
View Older Stories View More Recent Stories
-
Stem, Inc. and Partners Awarded 68 MWh in New Smart Energy Storage Projects for Disadvantaged and Low-Income California Communities (STPK)
-
Stem, Inc. and Partners Awarded 68 MWh in New Smart Energy Storage Projects for Disadvantaged and Low-Income California Communities
-
Gojek, Tokopedia in $18 billion merger talks for Indonesia's biggest deal
-
SEATech Updates Shareholders
-
Impossible Foods Donates Its Millionth Burger and Doubles Down on Social Good For 2021
-
Gojek invests in Bank Jago to accelerate financial inclusion in Indonesia
-
Exclusive: Indonesia e-commerce giant Tokopedia aims for $1 billion dual U.S., domestic IPO - sources
-
Alphabet's Verily raises $700 million in funding round
-
Verily Announces $700 Million Investment Round to Accelerate Key Businesses, Including Baseline and Verily Health Platforms
-
TurtleTree Labs raises US$6.2 million in Pre-A funding round
-
Keurig Dr Pepper Inc. (KDP) Names JAB Partner Justine Tan to Board, Anna-Lena Kamenetzky to Step Down
-
Keurig Dr Pepper Announces Appointment of New Director to its Board
-
Singapore to open travel bubble as it prepares to stand in for Davos
-
Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases
-
Investors swap China holdings from Wall Street to Hong Kong as delisting threat brews
-
Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027
-
Blaize Delivers First Open and Code-free AI Software Platform Spanning the Entire Edge AI Application Lifecycle
-
RESOLUTE 2.0 COVID-19 TEST KIT FIRST TO RECEIVE SINGAPORE HEALTH SCIENCES AUTHORITY’S APPROVAL FOR DEEP THROAT SALIVA TESTING
-
Conductor Raises an Additional $20 Million from Temasek, Expanding Latest Fundraising Round to $170 Million
-
Saving the City: London's finance district plots reboot as COVID compounds Brexit
-
Impossible Foods Hires Vanderbilt University Biochemistry Department Chair Dr. John D. York as Chief Science Officer
-
SoftBank leads $80 million round in healthcare startup Pear Therapeutics
-
Pear Therapeutics Completes $80M Series D Financing Led by SoftBank Vision Fund 2
-
Impossible Foods Details Extraordinary Impact of COVID-19 and Publishes All-New Sustainability Data in Annual Report
-
Stem to Combine with SPAC, Star Peak (STPK)
-
Stem, Inc. – Market Leader in AI-Driven Clean Energy Storage Systems – to Combine with Star Peak, Creating First Public Pure Play Smart Energy Storage Company
-
Singapore approves sale of lab-grown meat in world first
-
Spectral MD Appoints Dr. Jeffrey Carter as Chief Medical Consultant and Wan Lung Eng as Chief Financial Officer
-
SoundCloud Names Michael Weissman to Succeed Kerry Trainor as Chief Executive Officer in 2021
-
Impossible Foods and Feeding America® Fight to End Hunger With “Buy Impossible Burger, Give Impossible Burger” Holiday Campaign
-
Indonesia considers digital tax even without world consensus
-
SHIELD Announces DeviceSHIELD to Protect Small Businesses from Cyber Fraud During the COVID-19 Pandemic
-
Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China
-
Form SC 13G/A FTS International, Inc. Filed by: Temasek Holdings (Private) Ltd
-
Form SC 13D/A China Biologic Products Filed by: Temasek Holdings (Private) Ltd
-
Corbin Enters a New Era and Accelerates Its Impact
-
Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
-
China Biologic (CBPO) Enters into Definitive Merger Agreement for Going Private Transaction Valued at $4.76 Billion
-
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction
-
D3 Bio Launches with US$200 Million Investment to Develop Precision Medicines Addressing Unmet Patient Needs in Oncology & Immunology
-
Roth CH Acquisition I (ROCH) to Combine With PureCycle Technologies
-
Roth CH Acquisition I to Combine With PureCycle Technologies, Accelerating a Revolution in Plastics Recycling Through Impact Investing
-
Techstars Launches the Sustainability Challenge
-
Roth CH Acquisition I to Combine With PureCycle Technologies, Accelerating a Revolution in Plastics Recycling Through Impact Investing
-
ChickP Launches Non-GMO Chickpea Starch
-
Form 13F-NT Temasek Capital (Private For: Sep 30
-
Form 13F-HR Temasek Holdings (Privat For: Sep 30
-
Form 13F-NT Temasek Life Sciences For: Sep 30
-
Form SC 13G SQZ Biotechnologies Co Filed by: Temasek Holdings (Private) Ltd
-
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress

